Equity Insider News
Commentary
Issued on behalf of Avant Technologies
Inc.
VANCOUVER, BC, June 17,
2025 /PRNewswire/ -- Venture Capital continues to
flow in bunches into the AI in healthcare sector, with AI companies
capturing more than half of digital health funding in Q1.
Investors are seeking novel opportunities that tap into this space,
with private companies such as Ellipsis Health and
Autonomize AI recently receiving $45M and $28M respectively for their innovations. For
other investors seeking opportunities among publicly traded
companies, there's been plenty of development to follow from
innovators, including from Avant Technologies, Inc. (OTCQB:
AVAI), IQVIA Holdings Inc. (NYSE: IQV), SoundHound AI,
Inc. (NASDAQ: SOUN), RadNet, Inc. (NASDAQ: RDNT), and
The Cigna Group (NYSE: CI).
According to McKinsey's Global Institute, generative AI
isn't just a buzzword — it could deliver between $60 and $110
billion in annual value just within pharma and
medical products. Meanwhile, Statista now expects the
broader AI healthcare market to explode from $11 billion today to a staggering $188 billion by 2030, reflecting a major shift in
how technology is expected to transform patient care, diagnostics,
and operational efficiency.
For example, screenings for diabetic retinopathy are now live
across Costa Rica, Nicaragua, and Panama after Avant Technologies, Inc.
(OTCQB: AVAI) and joint-venture partner Ainnova Tech began
rolling out free Vision AI scans inside Grupo Dökka's
Fischel and La Bomba pharmacy chains. The quick,
non-invasive test looks for early retinal changes that often appear
before symptoms, then delivers secure results in minutes. By
placing the service in retail pharmacies—and preparing a parallel
launch in Mexico—the partners are moving care closer to patients
while collecting real-world evidence that can guide wider
commercialization.
"As we begin similar initiatives in Mexico, our goal is to close the patient care
loop with timely treatment, connecting every step of the journey,"
said Vinicio Vargas, CEO of
Ainnova Tech and board member of Ai-nova Acquisition
Corp. "We are integrating pharma, retail, ophthalmologists, and
our technology into a unified experience, all driven by one
incentive, the well-being of the diabetic patient."
The live-patient campaign gives Avant a timely proof
point as it works to bring Vision AI under one roof. Earlier this
month the company signed a non-binding letter of intent to acquire
100% of Ainnova, unifying leadership, intellectual
property, and data ahead of a scheduled FDA pre-submission
meeting in July. Folding the joint venture into a single public
entity would eliminate the current holding-company structure and
streamline everything from regulatory filings to revenue
recognition. Management believes the simplified cap table will
resonate with investors and prospective partners alike.
While the corporate lawyers handle due diligence, engineers are
putting final touches on a low-cost, automated retinal camera
designed to pair seamlessly with Vision AI. Traditional fundus
cameras can cost tens of thousands of dollars and require skilled
technicians. Avant's prototype is hands-free, feeds images
directly into the cloud platform, and is expected to ship at a
fraction of legacy pricing. If performance data match internal
tests, primary-care clinics and resource-constrained health systems
could screen large diabetic populations without adding specialist
staff.
Vision AI itself is also widening its clinical scope. A patented
dementia-risk module—combining a five-minute blood assay with AI
pattern recognition—remains in validation, while
cardiovascular-risk analytics are progressing through pilot studies
in Latin America. Each new
indication plugs into the same software backbone, positioning
Avant as a platform rather than a single-product story.
Financially, the merger would roll all outstanding
Ainnova equity into the publicly traded company, avoiding
cash dilution and aligning incentives for the combined team.
Leadership has signaled that post-deal capital raises, if needed,
would be targeted toward finishing the camera, scaling pharmacy
deployments, and supporting U.S. regulatory work.
Taken together, the live pharmacy screenings, pending
acquisition, and upcoming device launch mark a pivotal stretch for
Avant. The company is evolving from an AI incubator into a
full-stack diagnostics firm with proprietary hardware, a growing
menu of predictive algorithms, and on-the-ground distribution
partners. If the strategy holds, Vision AI could shorten referral
times, open earlier treatment windows, and give emerging-market
providers affordable access to specialist-level
insights—translating technology headlines into measurable patient
impact.
CONTINUED... Read this and more news for Avant
Technologies
at:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
IQVIA Holdings Inc. (NYSE: IQV) has launched a new
suite of AI agents tailored for the life sciences and healthcare
sectors.
"This is a pivotal opportunity to deliver the precise, efficient
workflows and insights required by the modern life sciences
industry," said Bhavik Patel,
President of Commercial Solutions of IQVIA. "Our
collaboration with NVIDIA helps us realize our vision to power
smarter healthcare for everyone, everywhere."
Built using NVIDIA's NIM Agent Blueprints and NeMo
platforms, these agentic tools aim to accelerate research,
streamline workflows, and improve clinical and commercial
decision-making. The rollout marks a major step in applying
domain-specific AI to real-world pharmaceutical challenges, from
target identification to HCP engagement.
SoundHound AI, Inc. (NASDAQ: SOUN) and Allina
Health have launched "Alli," a conversational AI agent designed
to improve the patient experience by automating key access points
in the healthcare system.
"Long wait times and administrative complexity can be a huge
source of stress for patients," said Michael Anderson, Executive Vice President of
Enterprise AI of SoundHound AI. "We are proud to partner
with Allina Health on this important digital transformation. The
organization is taking a forward-thinking approach by integrating
AI to support patients with immediate, personalized
assistance."
Deployed inside Allina Health's Customer Experience
Center, Alli connects directly with electronic medical records to
authenticate callers and manage appointments. With 80% of calls now
answered in under 45 seconds, the system has helped reduce wait
times while freeing up staff for more complex patient needs.
RadNet, Inc. (NASDAQ: RDNT) has acquired See-Mode
Technologies, a company specializing in AI-powered ultrasound
tools for thyroid and breast diagnostics.
"Early deployment of See-Mode's FDA-approved
thyroid ultrasound AI across a portion of our imaging centers has
demonstrated up to a 30% reduction in scan time," said Dr.
Howard Berger, President and Chief
Executive Officer of RadNet. "The increase in capacity
should improve our ability to drive better access and more revenue
through RadNet's existing centers."
The integration is expected to enhance operational capacity
across RadNet's imaging centers and add value to its
DeepHealth platform. With existing reimbursement pathways and a
high annual volume of ultrasound exams, the acquisition is
positioned to create new revenue opportunities and clinical
efficiencies.
Cigna Healthcare, a division of The Cigna Group
(NYSE: CI), has rolled out a suite of AI-powered tools through
its myCigna member portal to simplify key insurance tasks like
finding care, checking benefits, and tracking costs.
"Everyday moments in health care need to be easier," said
Katya Andresen, Chief Digital and
Analytics Officer of The Cigna Group. "These enhancements
are a significant step in our journey to transform the experience
and put customers at the heart of it."
These enhancements include an AI virtual assistant, real-time
cost tracking, personalized provider matching, and automated claim
support. Early results show high user engagement and improved
customer satisfaction, reinforcing Cigna's goal of making
health coverage more intuitive and accessible.
Source:
https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-
need-to-know/
CONTACT:
Equity
Insider
info@equity-insider.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be
considered as personalized financial advice. We are not licensed
under securities laws to address your particular financial
situation. No communication by our employees to you should be
deemed as personalized financial advice. Please consult a licensed
financial advisor before making any investment decision. This is a
paid advertisement and is neither an offer nor recommendation to
buy or sell any security. We hold no investment licenses and are
thus neither licensed nor qualified to provide investment advice.
The content in this report or email is not provided to any
individual with a view toward their individual circumstances.
Equity Insider is a wholly-owned subsidiary of Market IQ Media
Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies
Inc. advertising and digital media from the company directly. There
may be 3rd parties who may have shares Avant Technologies Inc., and
may liquidate their shares which could have a negative effect on
the price of the stock. This compensation constitutes a conflict of
interest as to our ability to remain objective in our communication
regarding the profiled company. Because of this conflict,
individuals are strongly encouraged to not use this publication as
the basis for any investment decision. The owner/operator of MIQ
own shares of Avant Technologies Inc. which were purchased in the
open market. MIQ reserves the right to buy and sell, and will buy
and sell shares of Avant Technologies Inc. at any time thereafter
without any further notice. We also expect further compensation as
an ongoing digital media effort to increase visibility for the
company, no further notice will be given, but let this disclaimer
serve as notice that all material disseminated by MIQ has been
approved by the above mentioned company; this is a paid
advertisement, and we own shares of the mentioned company that we
will sell, and we also reserve the right to buy shares of the
company in the open market, or through other investment vehicles.
While all information is believed to be reliable, it is not
guaranteed by us to be accurate. Individuals should assume that all
information contained in our newsletter is not trustworthy unless
verified by their own independent research. Also, because events
and circumstances frequently do not occur as expected, there will
likely be differences between any predictions and actual results.
Always consult a licensed investment professional before making any
investment decision. Be extremely careful, investing in securities
carries a high degree of risk; you may likely lose some or all of
the investment.
Logo:
https://mma.prnewswire.com/media/2644233/5374481/Equity_Insider_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ai-healthcare-funding-surges-as-real-world-rollouts-hit-pharmacies-hospitals-and-providers-302483975.html
SOURCE Equity Insider
